NOVO-NORDISK AS (NVO)

NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-23

$39.05-0.96%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge NOVO-NORDISK AS’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+1.1%

+10% or more+5%0%−5%−10% or less

21.94 → 22.18 EPS · FY ending Dec 31, 2027 · 7 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 7; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	76.81B
EPS	—	4.441
Annual ending 2026-12-31
Revenue	—	304.94B
EPS	—	22.382
Annual ending 2027-12-31
Revenue	—	310.87B
EPS	—	22.175

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage competitive pressure from Eli Lilly and patent expirations	A supporting condition in NOVO-NORDISK AS's published investment case. The stated target is No material loss of market share or revenue due to competition in FY26.	Intact	Significant market share loss or revenue decline from competition or patent expiry	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS at or above $21.6 in FY26	A primary condition in NOVO-NORDISK AS's published investment case. The stated target is >= $21.6.	Under Pressure	EPS falls below $20 in FY26	Diluted EPS: DKK 4.74 per share FY2026-Q2; GAAP. Published target: >= $21.6. Target and observation currencies differ. Source published Aug 4, 20264.74 DKK/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful launch and market expansion of Wegovy and obesity treatments	New product launches and partnerships support growth.	Intact	Failure to gain regulatory approval or market traction for Wegovy in China	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Total revenue at or above $293 billion in FY26	A primary condition in NOVO-NORDISK AS's published investment case. The stated target is >= $293 billion.	Under Pressure	total revenue falls below $270 billion in FY26	Revenue: DKK 78.488B FY2026-Q2; GAAP. Published target: >= $293 billion. Target and observation currencies differ. Source published Aug 4, 202678,488,000,000 DKK · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$22.18

$21.43 → $22.18 · observed estimates

FY2027 revenue$310.87B

$297.96B → $310.87B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$21.43	$297,962,479,466	7 / 15
2026-07-25	$21.43	$297,962,479,466	7 / 15
2026-07-26	$21.44	$298,255,072,702	7 / 16
2026-07-27	$21.44	$298,255,072,702	7 / 16
2026-07-28	$21.39	$300,213,387,560	8 / 27
2026-07-29	$21.39	$300,213,387,560	8 / 27
2026-07-30	$21.39	$300,213,387,560	8 / 27
2026-07-31	$21.39	$300,121,979,390	8 / 26
2026-08-01	$21.44	$298,228,150,526	7 / 16
2026-08-02	$21.25	$300,115,249,200	9 / 27
2026-08-03	$21.25	$300,115,249,200	9 / 27
2026-08-04	$21.44	$298,148,906,248	7 / 15
2026-08-05	$21.44	$298,148,906,248	7 / 15
2026-08-06	$21.44	$298,148,906,248	7 / 15
2026-08-07	$21.73	$301,832,502,425	8 / 16
2026-08-08	$21.61	$303,466,194,610	8 / 26
2026-08-09	$21.64	$303,677,734,720	8 / 26
2026-08-10	$21.73	$301,832,502,425	8 / 16
2026-08-12	$21.73	$304,526,084,370	8 / 26
2026-08-13	$21.73	$301,832,502,425	8 / 16
2026-08-14	$21.73	$301,832,502,425	8 / 16
2026-08-15	$21.73	$301,832,502,425	7 / 15
2026-08-16	$21.73	$301,832,502,425	7 / 15
2026-08-17	$21.73	$301,832,502,425	7 / 15
2026-08-18	$21.73	$301,832,502,425	7 / 16
2026-08-19	$21.73	$301,832,502,425	7 / 16
2026-08-20	$21.80	$303,665,415,103	7 / 16
2026-08-21	$21.80	$303,665,415,103	7 / 16
2026-08-22	$21.80	$303,665,415,103	7 / 16
2026-08-23	$21.80	$303,665,415,103	7 / 16
2026-08-24	$21.80	$303,665,415,103	7 / 16
2026-08-25	$21.86	$304,375,697,155	7 / 16
2026-08-26	$21.91	$304,527,247,608	7 / 16
2026-08-27	$21.91	$304,527,247,608	7 / 16
2026-08-28	$21.91	$304,527,247,608	7 / 16
2026-08-29	$21.92	$304,704,776,201	7 / 16
2026-08-30	$21.75	$304,704,776,201	7 / 16
2026-08-31	$21.75	$304,704,776,201	7 / 16
2026-09-01	$21.78	$305,199,007,343	7 / 16
2026-09-02	$21.78	$305,275,326,091	7 / 16
2026-09-03	$21.78	$305,594,532,841	7 / 16
2026-09-04	$21.78	$305,594,532,841	7 / 16
2026-09-05	$21.78	$305,602,282,397	7 / 16
2026-09-06	$21.78	$305,599,260,054	7 / 16
2026-09-07	$21.78	$305,599,260,054	7 / 16
2026-09-08	$21.78	$305,599,260,054	7 / 16
2026-09-09	$21.80	$305,599,260,054	7 / 16
2026-09-10	$21.82	$305,933,602,076	7 / 16
2026-09-11	$21.82	$305,959,783,289	7 / 16
2026-09-12	$21.81	$306,043,959,998	7 / 16
2026-09-13	$21.83	$306,227,951,311	7 / 16
2026-09-14	$21.83	$306,227,951,311	7 / 16
2026-09-15	$21.84	$306,296,196,961	7 / 16
2026-09-16	$21.82	$306,168,636,366	7 / 16
2026-09-17	$21.82	$306,213,288,590	7 / 16
2026-09-18	$21.82	$306,213,288,590	7 / 16
2026-09-19	$21.82	$306,213,288,590	7 / 16
2026-09-20	$21.98	$306,911,822,341	7 / 16
2026-09-21	$21.89	$305,643,962,150	7 / 16
2026-09-22	$21.92	$306,069,711,574	7 / 16
2026-09-23	$21.94	$305,148,989,009	7 / 16
2026-09-24	$21.94	$305,148,989,009	7 / 16
2026-09-25	$21.98	$306,226,101,016	7 / 16
2026-09-26	$21.98	$306,272,580,925	7 / 16
2026-09-27	$21.98	$306,272,580,925	7 / 16
2026-09-28	$22.05	$307,296,728,782	7 / 16
2026-09-29	$22.07	$307,617,505,620	7 / 16
2026-09-30	$22.07	$307,617,505,620	7 / 16
2026-10-01	$22.11	$308,222,799,134	7 / 16
2026-10-02	$22.15	$308,822,379,235	7 / 16
2026-10-03	$22.13	$308,471,421,084	7 / 16
2026-10-04	$22.13	$308,471,421,084	7 / 16
2026-10-05	$22.17	$309,088,635,036	7 / 16
2026-10-06	$22.12	$308,364,023,545	7 / 16
2026-10-07	$22.10	$308,039,882,904	7 / 16
2026-10-08	$22.08	$307,823,982,269	7 / 16
2026-10-09	$22.07	$307,760,852,544	7 / 16
2026-10-10	$22.07	$307,760,852,544	7 / 16
2026-10-11	$22.07	$307,706,077,636	7 / 16
2026-10-12	$22.10	$308,174,898,915	7 / 16
2026-10-13	$22.18	$308,757,820,011	7 / 16
2026-10-14	$22.23	$309,486,209,520	7 / 15
2026-10-15	$22.23	$309,597,684,404	7 / 15
2026-10-16	$22.30	$310,477,774,661	7 / 15
2026-10-17	$22.30	$310,477,774,661	7 / 15
2026-10-18	$22.27	$310,155,367,062	7 / 15
2026-10-19	$22.27	$310,154,537,014	7 / 15
2026-10-20	$22.20	$309,846,026,193	7 / 15
2026-10-21	$22.26	$311,034,404,566	7 / 15
2026-10-22	$22.26	$311,034,404,566	7 / 15
2026-10-23	$22.28	$311,298,452,392	7 / 15
2026-10-24	$22.18	$310,870,596,206	7 / 15

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	9	0
2026-06-01	5	10	0
2026-07-01	4	10	0
2026-08-01	4	11	0
2026-09-01	3	11	1
2026-10-01	3	10	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 10 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BMO CapitalOct 12 · prior Aug 6

$47.00 → $40.00-14.9%

$0$25.85$51.70

0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage competitive pressure from Eli Lilly and patent expirationsQualitative condition
EPS at or above $21.6 in FY26Published status: Under Pressure
Successful launch and market expansion of Wegovy and obesity treatmentsQualitative condition
Total revenue at or above $293 billion in FY26Published status: Under Pressure

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.2%Typical daily move · historical

Downside history

-43.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

NOVO-NORDISK AS outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is best described as a company-specific thesis with a supportive sector tailwind, but the evidence does not establish a clear business category or long-term direction. The thesis state is insufficient because there is not enough recent financial-performance history to assess it.

What's priced into NOVO-NORDISK AS

The evidence shows low fragility, meaning no listed warning signs suggest the current thesis is especially vulnerable. It does not provide enough valuation or expectations data to say whether NVO is cheap, fair, or expensive versus peers, or what the market already assumes.

What the fundamentals likely do

Near term, the stated chance of an earnings miss is low, though the evidence notes a deep miss in recent history and a downward trend in earnings surprises. The Healthcare backdrop has strengthened, but the evidence gives no recent company-level results or management execution details to support a clear multi-year fundamentals trajectory.

What NOVO-NORDISK AS hinges on

Near-term sector support depends partly on whether Healthcare bellwethers LLY, JNJ, and ABBV continue to report strong results and raise guidance. A weakening jobs trend could increase recession concerns, while weaker results or guidance from those bellwethers could reduce the sector tailwind; the evidence does not show how these factors affect NVO’s own business.